<DOC>
	<DOCNO>NCT01375829</DOCNO>
	<brief_summary>This phase I trial study side effect best dose ixabepilone temsirolimus treat patient solid tumor spread primary site place body remove surgery . Drugs use chemotherapy , ixabepilone , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Temsirolimus may stop growth tumor cell block enzymes need cell growth . Giving ixabepilone together temsirolimus may kill tumor cell .</brief_summary>
	<brief_title>Ixabepilone Temsirolimus Treating Patients With Solid Tumors That Are Metastatic Can Be Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximally tolerate dose ( MTD ) combination ixabepilone temsirolimus patient advance solid tumor . II . To describe toxicity profile associate combination ixabepilone temsirolimus . III . To assess preliminary efficacy combination ixabepilone temsirolimus . OUTLINE : This dose-escalation study . Patients receive ixabepilone intravenously ( IV ) 3 hour day 1 temsirolimus IV 30-60 minute day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3 month .</detailed_description>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Adult patient histologically confirm solid tumor malignancy metastatic unresectable standard curative measure therapy provide survival benefit exist longer effective Patients may two systemic therapeutic regimen metastatic disease set following exception : hormonal therapy ( e.g . tamoxifen , aromatase inhibitor , antiandrogen therapy , etc . ) Patients nonmeasurable , assessable , disease allow Absolute neutrophil count &gt; = 1500/mcL Hemoglobin &gt; = 9.0 g/dL Platelets &gt; = 100,000/mcL Total bilirubin &lt; 1.5 mg/dL Serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) = &lt; 2.5 x institutional upper limit normal ( ULN ) absence hepatic metastasis ; SGPT ( ALT ) = &lt; 3 x ULN SGOT ( AST ) = &lt; 5 x ULN presence hepatic metastasis Creatinine = &lt; 1.5 x ULN International normalize ratio ( INR ) = &lt; 1.4 patient warfarin ( Coumadin ) INR range 2.03.0 patient therapeutic dos warfarin ( Coumadin ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 Ability provide inform consent Willingness return Mayo Clinic institution follow Life expectancy &gt; = 84 day ( 12 week ) Women childbearing potential : negative serum pregnancy test do = &lt; 7 day prior registration Known standard therapy patient 's disease potentially curative definitely capable extend life expectancy Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , uncontrolled diabetes hemoglobin A1c ( HbA1C ) &gt; 8 , psychiatric illness/social situation would limit compliance study requirement Any follow prior therapy : Chemotherapy = &lt; 28 day prior registration Mitomycin C/nitrosoureas = &lt; 42 day prior registration Immunotherapy = &lt; 28 day prior registration Biologic therapy = &lt; 28 day prior registration Radiation therapy = &lt; 28 day prior registration Radiation &gt; 25 % bone marrow Failure fully recover acute , reversible effect prior chemotherapy regardless interval since last treatment New York Heart Association classification III IV Known central nervous system ( CNS ) metastases seizure disorder ; patient know brain metastasis successfully treat stable &gt; 6 month without requirement corticosteroid without seizure activity eligible Any follow : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFood Drug Administration [ FDA ] approve indication context research investigation ) Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen Immunocompromised patient ( relate use corticosteroid ) include patient know human immunodeficiency virus ( HIV ) positive Receiving investigational agent would consider treatment primary neoplasm History myocardial infarction = &lt; 168 day ( 6 month ) , congestive heart failure require use ongoing maintenance therapy lifethreatening ventricular arrhythmia &gt; = Grade 2 sensory neuropathy &gt; = Grade 2 hypertriglyceridemia &gt; = Grade 2 hypercholesterolemia Patients medication consider strong cytochrome P450 3A4 ( CYP3A4 ) inducer ( efavirenz , nevirapine , carbamazepine , phenobarbital , phenytoin , pioglitazone , rifabutin , rifampin , St. John 's wort ) CYP3A4 inhibitor ( indinavir , nelfinavir , ritonavir , clarithromycin , itraconazole , ketoconazole , nefazodone , saquinavir , telithromycin ) unless medication substitute another agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>